Table 3 HIV treatment and markers of immunity
From: HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya
| Variable | N | Median (IQR) or n (%) |
|---|---|---|
| Duration since diagnosis of HIV (Months) | 360 | 107.0 (71.5, 132.0) |
| Range (Min. – Max.) | 1.0–181.0 | |
| Duration before ART initiation (Months) | 360 | 44.0 (4.5, 78.5) |
| Range (Min. – Max.) | 0.0–166.0 | |
| Duration of ART use (Months) | 360 | 88.0 (51.0, 122.5) |
| Range (Min. – Max.) | 1.0–141.0 | |
| Duration of current ART (Months) | 360 | 51.0 (17.0, 76.0) |
| Range (Min. – Max.) | 0.0–147.0 | |
| ART Line | ||
| First line (NRTI + NNRTI) | 360 | 286 (79.4%) |
| Second line (NRTI + PI) | 74 (20.6%) | |
| Others | ||
| Dapsone | 5 (1.4%) | |
| Septrin | 359 | 353 (98.3%) |
| Septrin/Isoniazid | 1 (0.3%) | |
| Suppressed viral load (< 1000 copies/ml) | 358 | 303 (84.6%) |
| Baseline CD4 cell count per mm3 | 304 | 243.0 (10.8.0, 399.0) |
| Range (Min. – Max.) | 1.0–1459.0 | |
| < 200.0 | 122 (40.1%) | |
| 200.0–499.0 | 304 | 132 (43.4%) |
| ≥ 500.0 | 50 (16.4%) | |
| Current CD4 cell count per mm3 | 360 | 491.0 (336.5, 701.0) |
| Range (Min. – Max.) | 1.0–1845.0 | |
| < 200.0 | 33 (9.2%) | |
| 200.0–499.0 | 360 | 153 (42.5%) |
| ≥ 500.0 | 174 (48.3%) | |
| WHO Clinical stage | ||
| Stage 1 | 122 (35.6%) | |
| Stage 2 | 343 | 61 (17.8%) |
| Stage 3 | 132 (38.5%) | |
| Stage 4 | 28 (8.2%) | |